BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33208750)

  • 21. Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA.
    Kumari K; Das B; Adhya A; Chaudhary S; Senapati S; Mishra SK
    Cell Death Dis; 2018 Feb; 9(2):152. PubMed ID: 29396474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.
    Mabe NW; Fox DB; Lupo R; Decker AE; Phelps SN; Thompson JW; Alvarez JV
    J Clin Invest; 2018 Oct; 128(10):4413-4428. PubMed ID: 30148456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically.
    Mu X; Chen M; Xiao B; Yang B; Singh S; Zhang B
    DNA Cell Biol; 2019 Jul; 38(7):651-659. PubMed ID: 31140859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
    Rondinelli B; Gogola E; Yücel H; Duarte AA; van de Ven M; van der Sluijs R; Konstantinopoulos PA; Jonkers J; Ceccaldi R; Rottenberg S; D'Andrea AD
    Nat Cell Biol; 2017 Nov; 19(11):1371-1378. PubMed ID: 29035360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
    Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
    Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
    Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
    Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
    [No Abstract]   [Full Text] [Related]  

  • 37. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
    Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
    Huynh FC; Nguyen D; Jones FE
    Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
    Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
    Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
    Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
    Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.